Investigating radiotherapy’s impact on intestinal perforation risk in gastrointestinal tumor patients treated with bevacizumab

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 12

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Dec 15, 2025; 17(12): 110621
Published online Dec 15, 2025. doi: 10.4251/wjgo.v17.i12.110621

Table 2 Incidence of intestinal perforation, n (%)

Group	Incidence of intestinal perforation
Bevacizumab + radiotherapy group (n = 35)	4 (11.43)
Bevacizumab only group (n = 35)	0 (0.00)
χ²	4.242
P value	0.038

Citation: He WM, Li WS. Investigating radiotherapy’s impact on intestinal perforation risk in gastrointestinal tumor patients treated with bevacizumab. World J Gastrointest Oncol 2025; 17(12): 110621
URL: https://www.wjgnet.com/1948-5204/full/v17/i12/110621.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i12.110621

He WM, Li WS. Investigating radiotherapy’s impact on intestinal perforation risk in gastrointestinal tumor patients treated with bevacizumab. World J Gastrointest Oncol 2025; 17(12): 110621 [PMID: 41480214 DOI: 10.4251/wjgo.v17.i12.110621]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.